Dr. Gupta on BLASST-1 Results in Muscle-Invasive Bladder Cancer

Video

Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.

Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab (Opdivo), gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.

The BLASST-1 trial is exploring this regimen in the neoadjuvant setting of muscle-invasive bladder cancer, explains Gupta, adding that these are patients eligible to receive cisplatin. Patients received 4 cycles of the regimen, including nivolumab on day 8 of each cycle, and then cystectomy is performed within 6 to 8 weeks. The primary endpoint was pathologic downstaging to nonmuscle-invasive disease status; secondary endpoints were progression-free survival and safety. There were also a number of exploratory endpoints, she adds.

Results showed that the downstaging rate was 66%; the pathologic complete response rate was 49%, which is said to be significant for this patient population. Additionally, patients who had cT4N1 disease had a downstaging to pTa disease, Gupta concludes.

<<< View more from the 2020 Genitourinary Cancers Symposium

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH